Durvalumab plus tremelimumab alone or in combination with low-dose or hypofractionated radiotherapy in metastatic non-small-cell lung cancer refractory to previous PD(L)-1 therapy: an open-label, multicentre, randomised, phase 2 trial
Resource Type
Article
Authors
Schoenfeld, Jonathan D ; Giobbie-Hurder, Anita ; Ranasinghe, Srinika ; Kao, Katrina Z ; Lako, Ana ; Tsuji, Junko ; Liu, Yang ; Brennick, Ryan C ; Gentzler, Ryan D ; Lee, Carrie ; Hubbard, Joleen ; Arnold, Susanne M ; Abbruzzese, James L ; Jabbour, Salma K ; Uboha, Nataliya V ; Stephans, Kevin L ; Johnson, Jennifer M ; Park, Haeseong ; Villaruz, Liza C ; Sharon, Elad ; Streicher, Howard ; Ahmed, Mansoor M ; Lyon, Hayley ; Cibuskis, Carrie ; Lennon, Niall ; Jhaveri, Aashna ; Yang, Lin ; Altreuter, Jennifer ; Gunasti, Lauren ; Weirather, Jason L ; Mak, Raymond H ; Awad, Mark M ; Rodig, Scott J ; Chen, Helen X ; Wu, Catherine J ; Monjazeb, Arta M ; Hodi, F Stephen
Source
In The Lancet Oncology February 2022 23(2):279-291
Subject
Primary Research Articles
Language
ISSN
1470-2045